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Preliminarily, these results indicate community pharma-
cists are having a positive impact on treatment outcomes
and self-reported medication persistence of dyslipidemic
patients. CONCLUSIONS: Working collaboratively with
patients and physicians, pharmacists in this study pro-
vided a comprehensive dyslipidemia management pro-
gram that improved the treatment outcomes for dyslipi-
demic patients. As the debate continues concerning the
prescription versus non-prescription status of “statin”
therapies, studies such as this that indicate monitoring of
lipid lowering therapy can be instituted in varying ambu-
latory sites will provide useful data for professional and
regulatory groups.
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OBJECTIVES: To highlight the impact of post-fracture
treatment costs and time horizon on the cost-effectiveness
of hypothetical interventions. METHODS: A Markov
model was used to simulate the natural history of os-
teoporosis and the clinical, economic and health-related
quality of life impacts of a hypothetical post-menopausal
osteoporosis intervention. The intervention was assumed
to reduce all fractures (50% vertebral and hip; 25% wrist
and other), and cost $650 (US $) annually. The model
tracked the annual incidence of all fractures (vertebral,
hip, wrist, other), as well as mortality due to natural
causes and hip fractures. Age-specific mortality and frac-
ture incidence rates were derived from published US data
sources. Fracture rates were adjusted to reflect a patient
population at increased risk due to low BMD (T-score
2.5) and an existing vertebral fracture. Acute fracture
costs (within year of fracture) and annual fracture costs
in all years subsequent to the hip or vertebral fracture
were taken from the NOF status report (1998). RE-
SULTS: When patients were treated from 70 years of age
for five years and costs collected over a similar time
frame, the cost per QALY gained was estimated as ap-
proximately $20,000. When the treatment length re-
mained 5 years but the time horizon over which costs
were accumulated was increased to 30 years (or until
death), the incremental ratio approached a win-win (re-
duced costs, increased QALYs). Several analyses were
conducted to determine the components contributing to
this trend. CONCLUSIONS: Dramatic change in the
cost-effectiveness of an intervention can be produced by
modifying time horizon. The Canadian and other guide-
lines for economic evaluations recommend a time hori-
zon sufficient to capture all downstream therapy effects.
This work provides an example of the importance of time
horizon selection. In addition, it highlights the need for
accurate long-term costs of hip and vertebral fractures.
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OBJECTIVES: Rheumatoid arthritis and osteoarthritis
are important causes of morbidity in the population. The
objective of this study was to quantify the loss in health
related quality of life due to RA and OA diseases.
METHODS: 127 RA and 167 OA consecutive outpa-
tients were included in the study at 9 sites in the capital
and in the rest of Hungary in 1999. Both patient groups
filled in the EQ-5D questionnaire. In addition, RA pa-
tients filled in the HAQ while OA patients filled in the
WOMAC questionnaires. EQ-5D weighted index values
of the two patient groups were compared to those of the
general Hungarian population. HAQ and WOMAC
scores were correlated to EQ-5D weighted index values.
RESULTS: Five age groups were defined as people be-
tween the age of 35–44, 45–54, 55–64, 65–74, and
75–84. Mean EQ-5D weighted index values were 0.634,
0.517, 0.459, 0.34, and 0.34 among RA patients and
0.688, 0.429, 0.339, 0.415, and 0.359 among OA pa-
tients, respectively. Corresponding EQ-5D weighted in-
dex values are known to be 0.875, 0.813, 0.736, 0.705,
and 0.675 among the general population. Differences be-
tween the general population and the patients groups
were statistically significant (P  0.05). The correlation
coefficient between the EQ-5D weighted index and the
HAQ, WOMAC Pain, WOMAC Stiffness, WOMAC
Physical function scores were 0.552, 0.552, 0.187,
and 0.553, respectively. CONCLUSIONS: Rheumatoid
Arthritis and Osteoarthritis diseases lead to huge losses in
health related quality of life and this should be recog-
nized in global health statistics and in health policy prior-
ity setting.
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OBJECTIVE: Osteoporosis has little impact on mortal-
ity, but an important impact on health related quality of
life (QOL), but few experimental data about QOL loss
are available. The American National Osteoporosis Foun-
dation (NOF) avoided this problem by using an expert
panel. In this study a Dutch expert panel evaluated the
same post-fracture conditions. METHODS: The NOF
post-fracture conditions were evaluated by a panel using
the time trade-off method. Total burden of illness was
evaluated using a preexisting model fitted with Dutch
fracture data, assuming increased mortality after hip
fractures. In-hospital mortality directly after hip fractures
in men and women was assumed to correspond to this in-
creased mortality. RESULTS: The Dutch evaluations of
QALY loss in the first and subsequent years after fracture
were consistently lower than the US evaluations. Assum-
ing average health pre-fracture the QALY loss due to hip
fracture was estimated at 0.28 for the first year (0.47 in
the NOF report) and at 0.12 for subsequent years (vs.
0.17). For wrist fracture this was 0.03 vs. 0.05 for first
and 0.002 vs. 0.006 for subsequent years. For vertebral
fractures this was 0.04 vs. 0.05 for first year and 0.02 vs.
0.05 for subsequent years. Average loss of life in the pop-
ulation due to osteoporosis in general was evaluated for
women at 23 days. Average loss of health related QOL
was evaluated at 0.33 QALY’s. For men this loss was es-
timated at 15 days and 0.13 QALY’s respectively. CON-
CLUSIONS: The Dutch estimates of health related
QALY losses were lower than in the American evalua-
tion. Wrist fractures have little impact on overall burden
of illness, but the impact of vertebral fractures is propor-
tionally higher than expected due to the long-term QOL
effects. Although only 25% of hip fractures occur in men
the impact on mortality is proportionally higher.
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OBJECTIVES: To investigate patients’ drug therapy deci-
sion-making by modeling the relative importance of
treatment attributes affecting drug selection for erectile
dysfunction (ED). To identify distinct groups of respon-
dents with similar ratios for the selected drug attributes.
METHODS: A survey instrument was developed with
hypothetical drug profiles that reflected patient-defined
attributes of pharmaceutical therapies used to treat ED.
Conjoint analysis was used to analyze the asymmetrical
orthogonal array of product profiles based on three treat-
ment attributes, efficacy (EFF), side effects (SE), and
mechanism of action (ACT) identified from the literature
and previous research, as important variables in patient
decision-making for an ED therapy. Pearson’s r of the
conjoint model was used to test the correlation between
the observed and the estimated preference. Cluster analy-
sis was used to group respondents into unique clusters
based on ratios of the three product attributes. The nearest
centroid was the statistical algorithm used to determine
group membership. RESULTS: A total of 285 respon-
dents, seeking treatment for ED, completed the 12-item,
seven-page questionnaire during May and June 1998
while waiting to see their physician. Of these 285 survey
respondents, 256 (89.8%) completed all product profiles
and were included in the conjoint analyses. The Pearson’s
r for the overall model was 0.966 (P  0.0001), which
indicates that the predictive conjoint model fits the data.
Cluster analysis resulted in three distinct clusters, each
with a unique attribute importance structure. Respon-
dent members of Cluster 1, 2, and 3 had an EFF/SE/ACT
ratio of 2.1/4.2/1, 9.7/3.6/1, and 0.6/0.6/1, respectively.
CONCLUSION: This exploratory study provides insight
into patients’ therapy selection decision-making by pre-
senting the patient with hypothetical product profiles
simulating real-world choices between drug products.
Results indicated that respondent decision-making can be
modeled and that the resultant conjoint models and clus-
ter analyses can be used to predict relative drug product
preferences.
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INTRODUCTION: Patient satisfaction often impacts
patient adherence to treatment. The purpose of this study
was to develop and validate a treatment satisfaction
questionnaire that may be used for a variety of trials with
menopausal women. METHODS: Interviews with meno-
pausal women (N  62, UK, Germany, Netherlands, US
and Canada) served as the basis for the development of a
treatment satisfaction module (TSM). In-depth literature
reviews and clinician interviews were also conducted.
The face and content validity of the TSM was subse-
quently tested on 69 menopausal women taking HRT. Fi-
nally, the questionnaire was psychometrically validated
in a cross-sectional study in the US and Canada on 100
menopausal women currently taking HRT. RESULTS:
Interviews resulted in a core set of 14 items developed to
assess treatment effectiveness, satisfaction, expectations,
and behaviors. The validation study resulted in the dele-
tion of 1 item regarding patient knowledge about treat-
ment. The remaining 13 items yielded three factors: treat-
ment satisfaction, adherence/compliance and side effects.
